Endocan and Lumican in Relation to Cardiometabolic Risk in a Pediatric Overweight and Obese Cohort: A Cross-Sectional Study

Figure 4

Serum Endocan and Lumican levels in overweight and obese patients without NASH, with NASH, and healthy controls. No differences were observed between Lumican levels, and only significant differences between groups were highlighted after performing post hoc Bonferroni correction.